

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
ADDRESS: 102 CHI LANG STREET, THANH DONGI WARD, HAI PHONG CITY, VIETNAM  
TAXCODE: 0800011018



# **CONSOLIDATED FINANCIAL REPORT**

## **QUARTER IV, 2025**

*ESTABLISHED AT : DECEMBER 31,2025*

### **CONTENTS:**

- 1- BANLANCE SHEET
- 2- INCONME STATEMENT
- 3- CASH FLOWS STATEMENT
- 4- NOTES TO FINANCIAL STATEMENTS

Place of receipt : .....

## COMBINED BALANCE SHEET

Prepared as of: 31 / 12 / 2025

Unit: VND

Items	Code	Notes	Closing Balance	Opening Balance
1	2	3	4	5
<b>ASSET</b>				
<b>A – SHORT-TERM ASSETS</b>	<b>100</b>		<b>335.246.516.200</b>	<b>341.148.607.589</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>		<b>44.407.002.125</b>	<b>31.419.168.182</b>
1. Cash	111		44.407.002.125	31.419.168.182
2. Cash equivalents	112			
<b>II. Short-term investments</b>	<b>120</b>			
1. Trading securities	121			
2. Allowances for decline in value of trading	122			
3. Held to maturity investments	123			
<b>III. Short-term receivables</b>	<b>130</b>		<b>122.127.309.215</b>	<b>180.755.628.545</b>
1. Short-term trade receivables	131		109.868.189.942	118.236.171.594
2. Short-term repayments to suppliers	132		18.628.774.680	59.671.572.390
3. Short-term intra-company receivables	133			
4. Receivables under schedule of construction	134			
5. Short-term loan receivables	135			
6. Other short-term receivables	136		244.578.467	6.519.269.624
7. Short-term allowances for doubtful debts (*)	137		(6.614.233.874)	(3.671.385.063)
8. Shortage of assets awaiting resolution	139			
<b>IV. Inventories</b>	<b>140</b>		<b>144.111.967.142</b>	<b>127.909.053.084</b>
1. Inventories	141		144.111.967.142	127.909.053.084
2. Allowances for decline in value of inventories	149			
<b>V. Other current assets</b>	<b>150</b>		<b>24.600.237.718</b>	<b>1.064.757.778</b>
1. Short-term prepaid expenses	151		784.391.367	624.164.224
2. Deductible VAT	152		23.140.846.351	440.593.554
3. Taxes and other receivables from government	153			
4. Government bonds purchased for resale	154			
5. Other current assets	155		675.000.000	
<b>B – LONG-TERM ASSETS</b>	<b>200</b>		<b>618.788.353.172</b>	<b>305.237.748.766</b>
<b>I. Long-term receivables</b>	<b>210</b>			
1. Long-term trade receivables	211			
2. Long-term repayments to suppliers	212			
3. Working capital provided to sub-units	213			
4. Long-term intra-company receivables	214			
5. Long-term loan receivables	215			
6. Other long-term receivables	216			
7. Long-term allowances for doubtful debts (*)	219			
<b>II. Fixed assets</b>	<b>220</b>		<b>471.482.526.434</b>	<b>277.938.572.145</b>
<b>1. Tangible fixed assets</b>	<b>221</b>		<b>453.231.176.078</b>	<b>259.687.221.789</b>
- Historical costs	222		696.766.214.346	481.416.768.768
- Accumulated depreciation (*)	223		(243.535.038.268)	(221.729.546.979)
<b>2. Finance lease fixed assets</b>	<b>224</b>			
- Historical costs	225			
- Accumulated depreciation (*)	226			
<b>3. Intangible fixed assets</b>	<b>227</b>		<b>18.251.350.356</b>	<b>18.251.350.356</b>
- Historical costs	228		25.557.287.846	25.557.287.846



Items	Code	Notes	Closing Balance	Opening Balance
1	2	3	4	5
- Accumulated depreciation (*)	229		(7.305.937.490)	(7.305.937.490)
<b>III. Investment properties</b>	<b>230</b>			
- Historical costs	231			
- Accumulated depreciation (*)	232			
<b>IV. Long-term assets in progress</b>	<b>240</b>		<b>142.391.317.925</b>	<b>24.432.507.459</b>
1. Long-term work in progress	241			
2. Construction in progress	242		142.391.317.925	24.432.507.459
<b>V. Long-term investments</b>	<b>250</b>		<b>1.160.000.000</b>	
1. Investments in subsidiaries	251		1.160.000.000	
2. Investments in joint ventures and associates	252			
3. Investments in equity of other entities	253			
4. Allowances for long-term investments (*)	254			
5. Held to maturity investments	255			
<b>VI. Other long-term assets</b>	<b>260</b>		<b>3.754.508.813</b>	<b>2.866.669.162</b>
1. Long-term prepaid expenses	261		3.754.508.813	2.866.669.162
2. Deferred income tax assets	262			
3. Long-term equipment and spare parts for	263			
4. Other long-term assets	268			
<b>TOTAL ASSETS</b>	<b>270</b>		<b>954.034.869.372</b>	<b>646.386.356.355</b>
<b>RESOURCES</b>				
<b>C - LIABILITIES</b>	<b>300</b>		<b>450.724.137.958</b>	<b>192.127.190.710</b>
<b>I. Short-term liabilities</b>	<b>310</b>		<b>213.669.861.101</b>	<b>186.108.895.749</b>
1. Short-term trade payables	311		74.933.027.107	63.913.046.095
2. Short-term prepayments from customers	312		28.319.984.253	27.011.433.156
3. Taxes and other payables to government budget	313		10.112.678.819	7.152.037.955
4. Payables to employees	314		18.336.177.800	4.869.401.998
5. Short-term accrued expenses	315		604.089.126	428.162.066
6. Short-term intra-company payables	316			
7. Payables under schedule of construction contract	317			
8. Short-term unearned revenues	318		1.000.537.013	3.201.934.270
9. Other short-term payments	319		7.550.378.347	7.182.181.347
10. Short-term borrowings and finance lease	320		66.805.817.846	65.925.328.072
11. Short-term provisions (*)	321			
12. Bonus and welfare fund	322		6.007.170.790	6.425.370.790
13. Price stabilization fund	323			
14. Government bonds purchased for resale	324			
<b>II. Long-term liabilities</b>	<b>330</b>		<b>237.054.276.857</b>	<b>6.018.294.961</b>
1. Long-term trade payables	331			
2. Long-term repayments from customers	332			
3. Long-term accrued expenses	333			
4. Intra-company payables for operating capital	334			
5. Long-term intra-company payables	335			
6. Long-term unearned revenues	336			
7. Other long-term payables	337			
8. Long-term borrowings and finance lease	338		237.048.292.142	6.002.713.990
9. Convertible bonds	339			
10. Preference shares	340			
11. Deferred income tax payables	341			
12. Long-term provisions	342			
13. Science and technology development fund	343		5.984.715	15.580.971
<b>D - OWNER'S EQUITY</b>	<b>400</b>		<b>503.310.731.414</b>	<b>454.259.165.645</b>
<b>I. Owner's equity</b>	<b>410</b>		<b>503.310.731.414</b>	<b>454.259.165.645</b>
1. Contributed capital	411		359.959.290.000	279.473.170.000

Items	Code	Notes	Closing Balance	Opening Balance
1	2	3	4	5
- Ordinary shares with voting rights	411			
- Preference shares	411			
2. Capital surplus	412			
3. Conversion options on convertible bonds	413			
4. Other capital	414			
5. Treasury shares (*)	415			
6. Differences upon asset revaluation	416			
7. Exchange rate differences	417			
8. Development and investment funds	418		79.594.214.888	124.594.214.888
9. Enterprise reorganization assistance fund	419			
10. Other equity funds	420			
11. Undistributed profit after tax	421		63.757.226.526	50.191.780.757
- Undistributed profit after tax brought forward	421		8.425.031.277	9.870.172.861
- Undistributed profit after tax for the current	421		55.332.195.249	40.321.607.896
12. Capital expenditure funds	422			
<b>II. Funding sources and other funds</b>	<b>430</b>			
1. Funding sources	431			
2. Funds used for fixed asset acquisition	432			
<b>TOTAL SOURCES</b>	<b>440</b>		<b>954.034.869.372</b>	<b>646.386.356.355</b>

**Prepared by**  
(Signature and full name)



**Nguyễn Thị Quỳnh Nga**

**Chief accountant**  
(Signature and full name)




**KẾ TOÁN TRƯỞNG**  
**CNKT: CHU VĂN LONG**

January 27, 2026



**Director**  
(Signature, full name and stamp)



**TỔNG GIÁM ĐỐC**  
**DSCKI: NGUYỄN THỊ TÚ ANH**



## QUARTERLY COMBINED INCOME STATEMENT

Quarter: IV/2025

Unit: VND

Item	Code	Description	Quarter: IV		Accumulation from the beginning of the fiscal year to at the end of current quarter	
			Current period	Previous period	Current year	Previous year
1	2	3	4	5	6	7
1. Revenues from sales and services rendered	01	25	198.828.181.001	185.248.236.674	689.532.822.613	668.056.188.242
2. Revenue deductions	02		2.745.714.127	1.673.252.200	5.815.779.896	3.054.479.448
3. Net revenues from sales and services rendered	03		196.082.466.874	183.574.984.474	683.717.042.717	665.001.708.794
4. Costs of goods sold	04	27	128.233.436.498	124.210.008.882	438.256.546.994	454.770.265.987
5. Gross revenues from sales and services rendered	05		67.849.030.376	59.364.975.592	245.460.495.723	210.231.442.807
6. Financial income	06	26	283.161.278	365.334.189	1.217.152.638	633.188.787
7. Financial expenses	07	28	1.485.640.180	1.346.787.791	5.681.886.282	6.255.488.148
- In which: Interest expenses	23		813.748.412	717.018.754	3.177.483.945	3.218.208.599
8. Selling expenses	25		19.424.604.046	19.032.672.812	79.665.952.449	74.149.536.551
9. General administration expenses	26		25.494.452.207	24.877.767.043	93.000.995.009	81.814.791.647
10. Net profits from operating activities	30		21.727.495.221	14.473.082.135	68.328.814.621	48.644.815.248
11. Other income	31		382.831.767	418.952.019	1.983.041.896	2.152.468.731
12. Other expenses	32		30.000.000	130.486	546.295.012	8.775.306
13. Other profits	40		352.831.767	418.821.533	1.436.746.884	2.143.693.425
14. Total net profit before tax	50		22.080.326.988	14.891.903.668	69.765.561.505	50.788.508.673
15. Current corporate income tax expenses	51	30	4.524.619.927	3.000.406.976	14.061.666.832	10.179.727.977
16. Deferred corporate income tax expenses	52	30				
17. Profits after enterprise income tax	60		17.555.707.061	11.891.496.692	55.703.894.673	40.608.780.696
18. Basic earnings per share	70		488	330	1.548	1.128
19. Diluted earnings per share	71		488	330	1.548	1.128
20. Value per share	72		10.000	10.000	10.000	10.000

Prepared by

(Signature and full name)

Nguyễn Thị Quỳnh Nga

Chief Accountant

(Signature and full name)

KẾ TOÁN TRƯỞNG  
CNKT: CHU VĂN LONG

January 27, 2026

Director

(Signature, full name and stamp)



TỔNG GIÁM ĐỐC

ĐSCK I: NGUYỄN THỊ TÚ ANH



# CONCLUSIVE CASH FLOW STATEMENT

(By Indirect method)  
Quarter IV/2025

Unit: VND

Item	Code	Description	Accumulation from the beginning of the fiscal year to at the end of current quarter	
			This year	Previous year
1	2	3	4	5
<b>I. Cash flows from operating activities</b>				
1. Profit before tax	01		69.765.561.505	50.788.508.673
2. Adjustments for			33.934.871.256	33.971.175.549
- Depreciation of fixed assets and investment properties	02		27.896.857.741	27.261.433.809
- Provisions	03		2.942.848.811	3.671.385.063
- Gains (losses) on exchange rate differences from revaluation of accounts derived from foreign currencies	04		57.752.721	(50.857.754)
- Gains (losses) on investing activities	05		(140.071.962)	(128.994.168)
- Interest expenses	06		3.177.483.945	3.218.208.599
- Other adjustments	07		103.700.432.761	84.759.684.222
3. Operating profit before changes in working capital	08		32.310.217.722	(48.775.880.044)
- Increase (decrease) in receivables	09		(16.202.914.058)	(23.555.535.012)
- Increase (decrease) in inventories	10		(47.902.822.968)	40.089.010.412
- Increase (decrease) in payables (exclusive of interest payables, enterprise income tax payables)	11		(1.048.066.794)	4.803.425.508
- Increase (decrease) in prepaid expenses	12		(3.177.483.945)	(3.218.208.599)
- Increase (decrease) in trading securities	13		(11.535.675.825)	(5.592.091.588)
- Interest paid	14		0	0
- Enterprise income tax paid	15		(418.200.000)	(525.180.334)
- Other receipts from operating activities	16		-	-
- Other payments on operating activities	17		0	0
Net cash flows from operating activities	20		55.725.486.893	47.985.224.565
<b>II. Cash flows from investing activities</b>			0	0
1. Purchase or construction of fixed assets and other long-term assets	21	6,7,8,11	(267.499.306.224)	(25.268.805.054)
2. Proceeds from disposals of fixed assets and other long-term assets	22		99.149.092	181.809.091
3. Loans and purchase of debt instruments from other entities	23		(1.160.000.000)	0
4. Collection of loans and repurchase of debt instruments of other	24		0	0
5. Equity investments in other entities	25		0	0
6. Proceeds from equity investment in other entities	26			
7. Interest and dividend received	27		40.922.870	29.742.305
Net cash flows from investing activities	30		(268.519.234.262)	(25.057.253.658)
<b>III. Cash flows from financial activities</b>			0	0
1. Proceeds from issuance of shares and receipt of contributed capital	31	21	0	0
2. Repayments of contributed capital and repurchase of stock issued	32	21	0	0
3. Proceeds from borrowings	33		373.496.645.091	152.833.226.632
4. Repayment of principal	34		(141.570.577.165)	(163.680.154.573)
5. Repayment of financial principal	35		-	-
6. Dividends or profits paid to owners	36	21	(6.148.409.740)	(6.119.889.000)
Net cash flows from financial activities	40		225.777.658.186	(16.966.816.941)
Net cash flows during the fiscal year (20+30+40)	50		12.983.910.817	5.961.153.966
Cash and cash equivalents at the beginning of fiscal year	60		31.419.168.182	25.418.100.057
Effect of exchange rate fluctuations	61		3.923.126	39.914.159
Cash and cash equivalents at the end of fiscal year (50+60+61)	70	29	44.407.002.125	31.419.168.182

Prepared by  
(Signature and full name)

  
Nguyễn Thị Quỳnh Nga

Chief Accountant  
(Signature and full name)

  
KẾ TOÁN TRƯỞNG  
CNKT: CHU VĂN LONG

Day 27 Month 01 Year 2026  
Director  
(Signature, full name and stamp)

  
TỔNG GIÁM ĐỐC  
ĐSCKI: NGUYỄN THỊ TÚ ANH



## NOTES TO FINANCIAL STATEMENT

Quarter: IV/2025

### I. ENTERPRISE INFORMATION

#### 1. Form of ownership:

Hai Duong Pharmaceutical Medical Materials Joint Stock Company (the Company) was converted from Hai Duong Pharmaceutical and Medical Supplies Company according to Decision No. 5943/QD/UB dated December 17, 2002, by the Hai Duong Provincial People's Committee on the transformation of a state-owned enterprise into a joint-stock company. The Company operates under Business Registration Certificate No. 0403000046 issued by the Hai Duong Department of Planning and Investment on April 4, 2003; amended for the 23st time on Juny 16 , 2025 with the Enterprise Code: 0800011018.

#### 2. Fields

Manufacturing of pharmaceuticals, chemicals, and medicinal materials; manufacturing of medical, dental, orthopedic, and rehabilitation equipment; manufacturing of functional foods not elsewhere classified; manufacturing of cosmetics; wholesale of pharmaceuticals and medical equipment; wholesale of other foods; wholesale of perfumes, cosmetics, and hygiene products; wholesale of other chemicals; wholesale of medical machinery and equipment; other specialized wholesale not elsewhere classified; retail of pharmaceuticals, medical equipment, cosmetics, and hygiene products in specialized stores; retail of other chemicals not elsewhere classified in specialized stores; retail of other functional foods in specialized stores; retail of watches and eyewear in specialized stores; cultivation of medicinal plants; printing; other professional scientific activities not elsewhere classified; road freight transport; agency services; real estate business, land use rights owned, used, or leased; hotels; other personal service activities not elsewhere classified; distillation, rectification, and blending of spirits; production of wine; production of beer and malt beverages; production of non-alcoholic beverages, mineral water; construction of all types of buildings; construction of utility projects; construction of other civil engineering projects; demolition; site preparation; installation of electrical systems; installation of water supply, sewerage, heating, and air-conditioning systems; installation of other construction systems; completion of construction projects; other specialized construction activities; wholesale of beverages; retail of beverages in specialized stores; advertising; market research and public opinion polling; preschool education; organization of conventions and trade shows.

Authorized capital: 359.959.290.000 VND

(By words: Ba trăm năm mươi chín tỷ chín trăm năm mươi chín triệu hai trăm chín mươi nghìn đồng)

List of shareholders at 31/12/2025

Item	Type of shares	Number of shares	Value of shares	Contribution rate
- Individual shareholders	Ordinary shares	35.995.929	359.959.290.000	100%
Total		35.995.929	359.959.290.000	

Headquarters: Số 102, Phố Chi Lăng, Phường Thành Đông, Thành phố Hải Phòng, Việt Nam  
Taxcode: 0800011018

**V. Notes to the Balance sheet****1. Cash**

- Cash	
- Demand deposits	
- Cash equivalents (Deposits with maturity term under 3 months)	
<b>Total</b>	

<u>31-12-2025</u>	<u>01-01-2025</u>
3.688.332.243	2.584.400.686
40.718.669.882	28.834.767.496
<b>44.407.002.125</b>	<b>31.419.168.182</b>

**2. Financial investments****a) Trading securities**

- Total value of shares;	
- Total value of bonds;	
- Other financial investments;	
- Provision for Decline in Value of Trading Securities	

**b) Held to maturity investments**

- Term deposits	
- Bonds	
- Other investments	

**Total**

<u>31-12-2025</u>	<u>01-01-2025</u>
-------------------	-------------------

**3. Short-term trade receivables****a) Trade receivables**

- Detail

**b) Trade receivables from relevant entities**

- Detail

**Total**

<u>31-12-2025</u>	<u>01-01-2025</u>
<b>109.868.189.942</b>	<b>118.236.171.594</b>

**4. Short-term repayments to suppliers****a) Repayments to suppliers**

\*Detail in PL4

**b) Repayments to relevant entities**

- Detail

**Total**

<u>31-12-2025</u>	<u>01-01-2025</u>
<b>18.628.774.680</b>	<b>59.671.572.390</b>

**5. Short-term loan receivables**

- Short-term loan receivables

**Total**

<u>31-12-2025</u>	<u>01-01-2025</u>
-------------------	-------------------



<b>6. Other short-term receivables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Receivables from equitization;		
- Receivables from dividends and profits received;		
- Other receivables.	35.000.000	49.000.000
- Advance	155.711.472	6.399.614.849
Advance	51.821.055	68.450.775
- Expenditures on behalf of a third party;		2.204.000
- Receivables from employees;		
- Other	2.045.940	
<b>Total</b>	<b>244.578.467</b>	<b>6.519.269.624</b>
<b>7. Shortage of assets awaiting resolution</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Cash;</i>		
<i>b) Inventories;</i>		
<i>c) Fixed assets;</i>		
<i>d) Other assets.</i>		
<b>Total</b>		
<b>8. Bad debts</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Total value of receivables, overdue debts or no overdue doubtful debts;		
- Information about fines, deferred interest receivables, etc arising from overdue debts which are not recorded to revenues;		
- Recoverability of overdue debts.	6.614.233.874	3.671.385.063
<b>Total</b>	<b>6.614.233.874</b>	<b>3.671.385.063</b>
<b>9. Inventories</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Goods in transit;		
- Raw materials;	58.095.609.924	54.200.285.889
- Tools and supplies;	473.710.871	
- Work in progress;	12.156.670.958	15.202.316.672
- Finished goods;	66.590.004.113	52.911.355.963
- Goods;	6.795.971.276	5.595.094.560
- Consignments;		
- Goods in bonded warehouse.		
- Real estate		
- Provision for devaluation of stocks		
<b>Total</b>	<b>144.111.967.142</b>	<b>127.909.053.084</b>
- value of unused or degraded inventories which are unsold at the end of fiscal year; reasons and resolutions for unused or degraded inventories;		
- Value of inventories put up as collateral to ensure liabilities at the end of fiscal year;		
<b>10. Short-term prepaid expenses</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Prepaid expenses incurred from fixed asset operating lease;		
- Dispatched tools and supplies;	784.391.367	624.164.224
- Borrowings;		
- Other items		
<b>Total</b>	<b>784.391.367</b>	<b>624.164.224</b>
<b>11. Long-term trade receivables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade receivables</i>		
*Detail in PL4		
<i>b) Trade receivables from relevant entities</i>		
- Detail		
<b>Total</b>		
<b>12. Long-term repayments to suppliers</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Repayments to suppliers</i>		
*Detail in PL4		

*b) Repayments to relevant entities*

- Detail

Total

**13. Other long-term receivables**

- Receivables from equitization;
- Receivables from dividends and profits received;
- Other receivables.
- Advance;
- Deposits;
- Expenditures on behalf of a third party;
- Others
- Provision for long-term receivables

Total

**14. Increases or decreases in tangible fixed assets**

\*Detail in PL1a

**15. Increases or decreases in finance lease fixed assets**

**16. Increases or decreases in intangible fixed assets**

\*Detail in PL1b

**17. Long-term work in progress**

*a) Long-term work in progress*

*b) Construction in progress*

- Purchase;
- Capital investment;

\*Detail in PL1c

- Repair.

Total

**18. Long-term financial investments**

*a) Equity investments in other entities*

- Investments in subsidiaries
- Investments in joint ventures and associates;
- Investments in other entities;
- Provision for investments in other entities

*b) Held to maturity investments*

- Term deposits
- Bonds
- Loans
- Other investments

Total

**19. Long-term prepaid expenses**

- Prepaid expenses incurred from fixed asset operating lease;
- Dispatched tools and supplies;
- Borrowings;
- Other items

Total

**20. Deferred tax assets and deferred tax payables**

*a) Deferred tax assets*

- Corporate income tax rates used for determination of value of deferred tax assets
- Deferred tax assets related to unused taxable losses
- Deferred tax assets related to unused taxable incentives

31-12-2025

01-01-2025

31-12-2025

01-01-2025

31-12-2025

01-01-2025

142.391.317.925

24.432.507.459

14.724.084.575

127.667.233.350

24.432.507.459

142.391.317.925

24.432.507.459

31-12-2025

01-01-2025

1.835.000.000

1.160.000.000

675.000.000

1.835.000.000

31-12-2025

01-01-2025

3.754.508.813

2.866.669.162

3.754.508.813

2.866.669.162

31-12-2025

01-01-2025

20

20



- Deferred tax assets related to deductible temporary differences
- Balance of deferred income tax payables

**b) Deferred income tax payables**

- Corporate income tax rates used for determination of value of deferred income tax payables
- Deferred income tax payables arising from taxable temporary differences
- Balance of Deferred income tax payables

<b>21. Long-term equipment and spare parts for replacement</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<b>22. Other long-term assets</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<b>23. Short-term trade payables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade payables</i>	<i>74.933.027.107</i>	<i>63.913.046.095</i>
*Detail in PL4		
<i>b) Overdue debts</i>		
*Detail in PL4		
<i>c) Trade payables to relevant entities</i>		
- Detail		
<b>Total</b>	<b>74.933.027.107</b>	<b>63.913.046.095</b>
<b>24. Short-term prepayments from customers</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Prepayments from customers</i>	<i>28.319.984.253</i>	<i>27.011.433.156</i>
- Detail in PL4		
<i>b) Prepayments from relevant entities</i>		
- Detail		
<b>Total</b>	<b>28.319.984.253</b>	<b>27.011.433.156</b>
<b>25. Taxes and other payables to the State</b>		
*Detail in PL5		
<b>26. Short-term expenses</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Expenses for goods without vouchers	11.581.904	11.581.904
- Compensation for board members	532.507.222	356.580.162
- Advertisement expenses		
- Annual leave, holiday break expenses		
- Other accrued expenses	60.000.000	60.000.000
<b>Total</b>	<b>604.089.126</b>	<b>428.162.066</b>
<b>27. Short-term unearned revenues</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Unearned revenues;		
- Revenues from traditional client programs;		
- Other unearned revenues.	1.000.537.013	3.201.934.270
<b>Total</b>	<b>1.000.537.013</b>	<b>3.201.934.270</b>
<b>28. Other short-term payables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Surplus of assets awaiting resolution;		
- Funding of trade union;		
- Social insurance; Health insurance; Unemployment insurance;		
- Payables on equitization;		
- Deposits;		
- Dividends or profits payables;		
- Other payables.	7.550.378.347	7.182.181.347
<b>Total</b>	<b>7.550.378.347</b>	<b>7.182.181.347</b>
<b>29. Overdue debts</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<b>30. Borrowings and finance lease liabilities</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
*Detail in PL6		

<b>31. Short-term provisions</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Provisions for product warranty;		
- Provision for construction warranty;		
- Provision for enterprise restructuring;		
- Other provision payables (periodical fixed asset repair expenses, environmental restoration expenses, etc)		
<b>Total</b>		
<b>32. Long-term trade payables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Trade payables</i>		
*Detail in PL4		
<i>b) Overdue debts</i>		
*Detail in PL4		
<i>c) Trade payables to relevant entities</i>		
- Detail		
<b>Total</b>		
<b>24. Long-term prepayments from customers</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>a) Prepayments from customers</i>		
*Detail in PL4		
<i>b) Prepayments from relevant entities</i>		
- Detail		
<b>Total</b>		
<b>34. Long-term provisions</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Provisions for product warranty;		
- Provision for construction warranty;		
- Provision for enterprise restructuring;		
- Other provision payables (periodical fixed asset repair expenses, environmental restoration expenses, etc)		
<b>Total</b>		
<b>35. Long-term unearned revenues</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Detail		
- The possibility of failure to perform a contract		
<b>Total</b>		
<b>28. Other long-term payables</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
- Deposits;		
- Other payables		
<b>Total</b>		
<b>37. Bonds issued</b>	<b><u>31-12-2025</u></b>	<b><u>01-01-2025</u></b>
<i>Common bonds</i>		
<i>a) Bonds issued</i>		
- Bonds issued according to par value;		
- Bonds issued at a discount		
- Bonds issued at premium.		
<b>Total</b>		
<i>b) Detailed description of bonds held by entities (each type of bonds in details)</i>		
<i>Convertible bond</i>		
<i>a) Value of convertible bond</i>		
Equity Structure		
Initial recorded principal debt structure (1)		
Bond issuance costs pending allocation (2)		
Total: Cumulative allocated value of the discount amount		
Opening balance		



Increase in allocation during the year

Closing balance (2)

Principal debt structure at year-end = (1) - (2)

*b) Detailed description of bonds held by entities (each type of bonds)*

	<u>31-12-2025</u>	<u>01-01-2025</u>
<b>38. Owner's equity</b>		
<i>a) Comparison table of owner's equity fluctuations</i>		
*Detail in PL2		
<i>b) Contributed capital</i>	<b>359.959.290.000</b>	<b>279.473.170.000</b>
Contributed capital of State		
Contributed capital of Individual	359.959.290.000	279.473.170.000
<i>c) Capital transactions with owners and distribution of dividends or profits</i>	<b>359.959.290.000</b>	<b>279.473.170.000</b>
- Owner's invested equity	359.959.290.000	279.473.170.000
+ Opening equity		
+ Increase in capital during the fiscal year		
+ Decrease in capital during the fiscal year		
+ Closing capital	359.959.290.000	279.473.170.000
- Dividends or distributed profits		
<i>d) Shares</i>		
- Number of shares registered for issuance	35.995.929	27.947.317
- Number of shares sold public market	35.995.929	27.947.317
+ Common shares	35.995.929	27.947.317
+ Preference shares (type of shares classified as owner's equity)		
- Number of shares repurchased (treasury shares)		
+ Common shares		
+ Preference shares (type of shares classified as owner's equity)		
- Number of shares outstanding	35.995.929	27.947.317
+ Common shares	35.995.929	27.947.317
+ Preference shares (type of shares classified as owner's equity)		
* Par value of shares outstanding	10.000	10.000
<i>e) Funds of enterprises:</i>	<b>79.594.214.888</b>	<b>124.594.214.888</b>
- Development investment funds;	79.594.214.888	124.594.214.888
- Enterprise restructuring funds;		
- Other funds.		
<b>39. Exchange differences</b>	<u><b>31-12-2025</b></u>	<u><b>01-01-2025</b></u>
- Exchange differences due to change from financial statement prepared in foreign currency to VND		
- Exchange differences due to other reasons (detailed reasons)		
<b>Total</b>		
<b>40. Funding sources</b>	<u><b>31-12-2025</b></u>	<u><b>01-01-2025</b></u>
- Funding sources granted during the fiscal year		
- Non-business expenses		
- Closing remaining funding sources		
<b>VII. Notes to the Balance sheet</b>		
<b>1. Revenues from sales and services rendered</b>	<u><b>Current Year</b></u>	<u><b>Previous Year</b></u>
<i>a) Revenues from sale</i>	<b>198.828.181.001</b>	<b>185.248.236.674</b>
- Revenues from sale	196.884.362.100	181.146.663.670
- Revenues from services rendered	1.943.818.901	4.101.573.004
- Other revenues		
<i>b) Revenues from relevant entities (every entity in details)</i>		
- Detail		
<b>Total</b>	<b>198.828.181.001</b>	<b>185.248.236.674</b>

		<u>Current Year</u>	<u>Previous Year</u>
<b>2. Revenue deductions</b>			
- Trade discounts;		2.355.823.136	1.164.799.918
- Sales rebates;		39.734.665	6.042.374
- Sales returns;		350.156.326	502.409.908
<b>Total</b>		<b>2.745.714.127</b>	<b>1.673.252.200</b>
		<u>Current Year</u>	<u>Previous Year</u>
<b>5. Net revenues from sales and services rendered</b>			
- Net revenues from sales		194.138.647.973	179.473.411.470
- Net revenues from services rendered		1.943.818.901	4.101.573.004
- Net revenues from other sources			
<b>Total</b>		<b>196.082.466.874</b>	<b>183.574.984.474</b>
		<u>Current Year</u>	<u>Previous Year</u>
<b>3. Costs of goods sold</b>			
- Costs of goods sold;		55.233.100.565	65.615.973.736
- Costs of finished goods sold;		73.000.335.933	58.594.035.146
<b>Total</b>		<b>128.233.436.498</b>	<b>124.210.008.882</b>
		<u>Current Year</u>	<u>Previous Year</u>
<b>4. Financial income</b>			
- Interests of deposits or loans		12.798.938	8.692.056
- Interests of investments;			
- Dividends, distributed profits;			
- Interests of exchange differences;		270.362.340	356.642.133
- Interests of sale under deferred payment or payment discounts;			
- Other financial incomes.			
<b>Total</b>		<b>283.161.278</b>	<b>365.334.189</b>
		<u>Current Year</u>	<u>Previous Year</u>
<b>5. Financial expenses</b>			
- Interests of loans;		813.748.412	717.018.754
- Payment discounts or interests of sale under deferred payment;		296.437.207	304.175.237
- Losses due to disposal of financial investments;			
- Losses of exchange differences;			
- Allowances for decline in value of trading securities and investment impairment;			
- Other financial expenses;		375.454.561	325.593.800
- Decreases in financial expenses.			
<b>Total</b>		<b>1.485.640.180</b>	<b>1.346.787.791</b>
		<u>Current Year</u>	<u>Previous Year</u>
<b>7. Selling expenses and general administration expenses</b>			
<i>a) General administration expenses incurred during the fiscal year</i>		<b>25.494.452.207</b>	<b>24.877.767.043</b>
- Administration staff expenses		9.833.537.944	10.265.434.781
- Administrative materials expenses		2.425.592.534	1.911.801.269
- Expenses of tools and supplies		754.206.831	296.957.718
- Depreciation expenses of fixed assets		1.003.568.397	1.009.489.739
- Taxes, fees and charges		20.114.296	141.101.071
- Provision expenses		2.851.981.649	4.639.626.005
- Outsourcing services expenses		1.858.099.451	1.959.384.632
- Other cash expenses		6.747.351.105	4.653.971.828
<i>b) Selling expenses incurred during the fiscal year</i>		<b>19.424.604.046</b>	<b>19.032.672.812</b>
- Selling staff expenses		12.451.378.322	13.279.635.169
- Materials and packing expenses			
- Tools and supplies expenses			
- Depreciation expenses of fixed assets		577.572.514	640.838.032
- Warranty expenses			
- Outsourcing services expenses		2.537.950.933	1.820.873.200



- Other cash expenses	3.857.702.277	3.291.326.411
<i>c) Decreases in selling expenses and general administration expenses</i>		
- Reversion of provisions for good warranty;		
- Reversion of provisions for enterprise reorganizing, other provisions;		
- Other decreases.		
<b>Total</b>	<b>44.919.056.253</b>	<b>43.910.439.855</b>
<b>8. Other income</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Disposal or transfer of fixed asset;	31.818.182	
- Gains from revalue of assets;		
- Collected fines;		
- Deductible taxes;		
- Other items.	351.013.585	418.952.019
<b>Total</b>	<b>382.831.767</b>	<b>418.952.019</b>
<b>9. Other expenses</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Residual value of fixed assets and expenses incurred from transfer or disposal of fixed assets;		
- Losses due to revaluation of assets;		
- Fines;		
- Other items.	30.000.000	130.486
<b>Total</b>	<b>30.000.000</b>	<b>130.486</b>
<b>10. Corporate income tax expenses of the current year</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
<i>a. Total net profit before tax</i>	<i>22.080.326.988</i>	<i>14.891.903.668</i>
<i>b. Increase (decrease) total profit before corporate income tax</i>	<i>542.772.647</i>	<i>110.131.212</i>
- Increase		
- Decrease		
<i>c. Total taxable income (a) + (b)</i>	<i>22.623.099.635</i>	<i>15.002.034.880</i>
<i>d. Corporate income tax rate</i>		
<i>e. Adjustment to increase corporate income tax of previous years</i>		
<i>f. Corporate income tax = {(c)*(d)}+(e)</i>	<i>4.524.619.927</i>	<i>3.000.406.976</i>
<b>11. Earnings per share / Diluted EPS</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
Profits after enterprise income tax	17.555.707.061	11.891.496.692
Bonus and welfare fund		
Average shares outstanding		
Earnings per share / Diluted EPS		
<b>12. Operating Costs Classified by Element</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Raw materials cost	87.841.734.731	78.876.908.640
- Labour cost	31.838.665.453	32.412.949.763
- Depreciation expenses of fixed assets	6.974.862.119	6.903.089.025
- Outsourcing services expenses	11.974.066.673	11.794.114.966
- Other cash expenses	16.656.948.692	14.934.784.302
<b>Total</b>	<b>155.286.277.668</b>	<b>144.921.846.696</b>
<b>13. Deferred corporate income tax expenses</b>	<b><u>Current Year</u></b>	<b><u>Previous Year</u></b>
- Total deferred corporate income tax expenses.		

## VIII. OTHER INFORMATION

### 1. Potential debts, commitments and other financial information:

No contingent liabilities have arisen from past events that could affect the information presented in the consolidated financial statements, which the Company does not

## 2. Events occurring after the fiscal-year end:

No events have occurred that could affect the information presented in the consolidated financial statements or that could significantly impact the Company's operations.

## 3. Information about relevant entities

### a) List of relevant entities

### b) Significant transactions with related parties in fiscal year

### c) Balances with related parties

Transactions with other related parties:

## 4. Segment report

## 5. Financial instrument

### Financial assets

	31-12-2025	01-01-2025
Cash and cash equivalents	44.407.002.125	31.419.168.182
Trade and other receivable	110.112.768.409	124.755.441.218
Available For Sale		
Short-term investments		
Provision	(6.614.233.874)	(3.671.385.063)
Total	147.905.536.660	152.503.224.337
Equity instruments		
Trade and orther payables	82.483.405.454	71.095.227.442
Accrued expenses	604.089.126	428.162.066
Borrowings	303.854.109.988	71.928.042.062
Total	386.941.604.568	143.451.431.570

### Liquidity Risk

\*Detail in PL7

## 6. Financial indicators of business performance

\*Detail in PL3

## 7. Income of the Board of Directors, CEO, and Supervisory Board

### 7.1. Income of the Board of Directors, CEO

	Position	Total Income
Nguyễn Trung Việt	Chairman of the BOD	631.624.049
Trần Phúc Dương	Member of the BOD	500.396.800
Nguyễn Thị Tú Anh	Member of the BOD, Chief Executive Officer	924.081.318
Đặng Văn Việt	Quality Director	435.254.120
Phạm Văn Năm	Sales Director	877.222.670

### 7.2. Income of Supervisory Board

Phạm Thị Thùy	Head of the SB	378.331.318
Trần Kim Cương	Member of the SB	350.039.538
Nguyễn Thị Hương Lan	Member of the SB	479.628.775

## 8. Comparative Information

## 9. Information on Going Concern

There are no events that cast significant doubt on the company's ability to continue as a going concern, and the company has no intention nor is it required to cease operations or significantly reduce its scale of operations.

Prepared by  
(Signature and full name)

Nguyễn Thị Quỳnh Nga

Chief accountant  
(Signature and full name)

KẾ TOÁN TRƯỞNG  
CNKT: CHU VĂN LONG

Day 27 month 01 year 2026  
Director  
(Signature, full name and stamp)  
HẢI DƯƠNG

TỔNG GIÁM ĐỐC  
ĐSCK I: NGUYỄN THỊ TÚ ANH



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**01a: The increase, decrease of tangible fixed assets**

No	Items	House, architecture	Machines, devices	Means of transmission transportation	Management tools	Total
<b>I</b>	<b>Purchase during the fiscal year</b>					
	Opening balance	172.733.683.489	285.473.219.986	20.264.529.754	2.945.335.539	481.416.768.768
	- Liquidation		(5.234.802.272)	(723.684.246)	(142.476.190)	(6.100.962.708)
	- Increase from capital construction		432.066.000			432.066.000
	- Increase by purchasing		221.018.342.286			221.018.342.286
	- Increase by other reasons		1.087.429.000			1.087.429.000
	Closing balance	172.733.683.489	501.688.826.000	19.540.845.508	2.802.859.349	696.766.214.346
<b>II</b>	<b>Value of accumulated depreciation</b>					
	Opening balance	57.275.571.913	142.365.068.240	19.176.546.292	2.912.360.534	221.729.546.979
	- Depreciation during the fiscal year	4.810.155.080	22.586.528.692	485.051.349	24.718.876	27.906.453.997
	- Liquidation		(5.234.802.272)	(723.684.246)	(142.476.190)	(6.100.962.708)
	Closing balance	62.085.726.993	159.716.794.660	18.937.913.395	2.794.603.220	243.535.038.268
<b>III</b>	<b>Remaining value</b>					
	Opening balance	115.458.111.576	143.108.151.746	1.087.983.462	32.975.005	259.687.221.789
	Closing balance	110.647.956.496	341.972.031.340	602.932.113	8.256.129	453.231.176.078

Closing residual value of tangible fixed asset put up as collateral for loans

Fully depreciated fixed assets still being used

119.775.998.041

The commitments to the purchase and sale of tangible fixed assets with great value in the future

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**01b: The increase, decrease of intangible fixed assets**

No	Items	Land use right	Issuing right	Copyright, patent	Other intangible fixed assets	Total
<b>I</b>	<b>Purchase during the fiscal year</b>					
	Opening balance	20.651.287.846			4.906.000.000	25.557.287.846
	Closing balance	20.651.287.846			4.906.000.000	25.557.287.846
	Value of accumulated depreciation					
<b>II</b>	<b>Opening balance</b>	2.399.937.490			4.906.000.000	7.305.937.490
	- Depreciation during the fiscal year					
	Closing balance	2.399.937.490			4.906.000.000	7.305.937.490
	Remaining value					
<b>III</b>	<b>Opening balance</b>	18.251.350.356				18.251.350.356
	Closing balance	18.251.350.356				18.251.350.356
	Closing residual value of tangible fixed asset put up as collateral for loans					

Fully depreciated fixed assets still being used

7.305.937.490

The commitments to the purchase and sale of tangible fixed assets with great value in the future



**Appendix 01c - Construction in progress**

No.	Construction in progress	Opening balance	Closing balance
7114317	Giàn thao tác máy tạo hạt		167.400.000
7114348	Máy hấp tiệt trùng hơi nước, Model SGLS-A-990D		1.233.199.750
7114349	Máy rửa dụng cụ theo chuẩn GMP, Model YQG-D-V-1.5H		2.167.835.350
7114417	Tủ sấy chân không cho dung môi cháy		220.000.000
7114418	Tủ sấy đối lưu tự nhiên		68.000.000
7114419	Tủ ủ vi khuẩn		144.560.000
7114420	Tủ ủ E.Coli		72.330.000
7114421	Tủ ổn định 1000L		390.000.000
7114435	Máy khử bụi dạng nghiêng lên, model: C&C200E+MD		530.549.500
7114436	Máy đánh bóng viên nang, model: C&C100CDS		556.879.500
7114456	Tủ sấy đối lưu tự nhiên		68.000.000
7114457	Tủ ủ vi khuẩn		144.560.000
7114458	Tủ ổn định 1000L		390.000.000
7114459	Tủ ổn định 1000L		390.000.000
7114460	Tủ ổn định 1000L		390.000.000
7114646	Tủ ủ vi nấm, model: KB ECO-400		210.000.000
7114647	Tủ ủ vi nấm, model: KB ECO-400		210.000.000
7114673	Thiết bị sắc ký khí, model: Agilent 8890 GC System, hãng sx: Agilent Technologies		1.547.000.000
7114674	Máy hấp tiệt trùng, model: SLSS-A-140D-S		822.367.075
7114676	Nồi hấp tiệt trùng có sấy, Model: CL-40LDP		254.200.000
7114677	Nồi hấp tiệt trùng Model CL-40L		162.100.000
7114678	Máy ủ nhiệt khô 4 block gia nhiệt Model QBD4		57.000.000
7114681	Cân phân tích 6 số lẻ, Model: MCA36S-3S00-D QP1 HWL		866.600.000
7114682	Cân phân tích 4 số lẻ, Model: QTX224IRU-1S, dòng cân Quintix Pro		106.400.000
7114683	Cân phân tích 4 số lẻ, Model: QTX224IRU-1S, dòng cân Quintix Pro		106.400.000
7114684	Hệ Thống Kiểm Tra Độ Vô Trùng Khép Kín, Model:		534.000.000
7114685	Tủ an toàn sinh học 1.2M, Model: Bioptima 4		238.000.000
7114686	Thiết bị đồ đĩa môi trường tự động, Model: Distriwel 440		722.800.000
7114687	Nồi hấp chuẩn bị môi trường, Model: Mediawel 10		522.400.000
7114690	Tủ an toàn sinh học 1.2M, Model: Bioptima 4		238.000.000
7114691	Tủ an toàn sinh học 1.2M, Model: Bioptima 4		238.000.000
7114692	Tủ an toàn sinh học 1.2M, Model: Bioptima 4		238.000.000
7114751	Hệ tiền xử lý nước thải Beta Lactam		717.503.400
	<b>Total</b>	<b>0</b>	<b>14.724.084.575</b>
	<b>Tk 2412 - CF Đầu tư XDCB dở dang</b>		
19	Chi phí tư vấn GMP EU dây chuyền cephalosporin - Dự án GĐ2	5.921.925.093	7.855.735.015
23	Chi phí tư vấn + thiết kế và ĐTXD Dây chuyền Cepharlosprorin GMPEU - Dự án GĐ2	12.855.006.168	101.807.305.355
34	Hệ thống PCCC nhà sản xuất 4c	0	2.915.476.350

35	Chi phí tài liệu thẩm định GMP EU của D/C đóng bột Cephalosprin	0	639.079.032
Chi phí TCDA	Chi phí lãi vay trung hạn của dự án	0	8.619.146.666
QSD L09 -54	Giá trị quyền sử dụng đất L09-54 Tại Cần Thơ	2.827.788.099	2.915.245.466
QSD L09-53	Giá trị Quyền sử dụng đất lô L09-53 Tại Cần Thơ	2.827.788.099	2.915.245.466
	<b>Total</b>	<b>24.432.507.459</b>	<b>127.667.233.350</b>
	<b>Total</b>	<b>24.432.507.459</b>	<b>142.391.317.925</b>



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**

102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**Appendix 01: Comparison table of owner's equity fluctuations**

Item	Contributed capital	Surplus equity	Other capital	Investment and development fund	Other funds	Undistributed profits after tax and funds	Total
Opening balance at 01/01/2024	203.996.300.000			174.594.214.888		41.544.595.561	420.135.110.449
Increase in capital in fiscal year	75.476.870.000					40.608.780.696	116.085.650.696
- Profits						40.608.780.696	40.608.780.696
- Increase in capital	75.476.870.000						75.476.870.000
- Spend funds							
Decrease in capital in fiscal year				50.000.000.000		31.961.595.500	81.961.595.500
- Dividends or distributed profits						6.119.889.000	6.119.889.000
- Set aside funds				50.000.000.000		25.476.870.000	75.476.870.000
- Other				0		364.836.500	364.836.500
Closing balance at 31/12/2024	279.473.170.000			124.594.214.888		50.191.780.757	454.259.165.645
Opening balance at 01/01/2025	279.473.170.000			124.594.214.888		50.191.780.757	454.259.165.645
Increase in capital in fiscal year	80.486.120.000					55.700.372.309	136.186.492.309
- Profits						55.700.372.309	55.700.372.309
- Increase in capital	80.486.120.000						80.486.120.000
- Spend funds							
Decrease in capital in fiscal year				45.000.000.000		42.134.926.540	87.134.926.540
- Dividends or distributed profits						6.148.409.740	6.148.409.740
- Set aside funds				45.000.000.000		35.486.120.000	80.486.120.000
- Other				0		500.396.800	500.396.800
Closing balance at 31/12/2025	359.959.290.000			79.594.214.888		63.757.226.526	503.310.731.414

- The company issues shares to increase its charter capital from the owner's equity according to the Resolution of the General Meeting of Shareholders No. 27/NQ-ĐHČĐ-DHD dated April 3, 2025, at a ratio of 100:28,8 (for every 100 shares owned, shareholders will receive 28,8 additional issued shares). The specific capital source for the issuance is as follows:

+ Development Investment Fund	45.000.000.000 VND
+ Undistributed after-tax profit.	35.486.120.000 VND
<b>Total</b>	<b>80.486.120.000 VND</b>

The company has completed the registration for additional stock trading in accordance with Decision No. 742/QĐ - SGDCKHN, dated June 20, 2025, issued by the Vietnam Securities Depository and Clearing Corporation. Accordingly, the number of additional registered shares for trading is 8,048,612 shares, with a par value of 10,000 VND per share. The total par value of the additional registered shares for trading is 80,486,120,000 VND.

- The company paid dividends from the profits of 2024: 6,148,409,740 VND (at a rate of 2,2%) according to the Resolution of the General Meeting of Shareholders No. 27/NQ-ĐHČĐ-DHD dated April 3, 2025.



**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**

102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**Appendix 03. Key indicators for assessing the overall financial condition and business performance**

Item	Measurement	Current year at 31/12/2025	Previous year at 31/12/2024
<b>6.1. Capital Structure and Assets Structure</b>			
<i>a. Assets Structure</i>			
- Fixed Assets / Assets	%	64,86	47,22
- Current Assets / Assets	%	35,14	52,78
<i>b. Capital Structure</i>			
- Trade payables / Total capital	%	47,24	29,72
- Owner's equity / Total capital	%	52,76	70,28
<b>6.2. Liquidity</b>			
a. General liquidity	times	2,12	3,36
b. Short-term liquidity	times	1,57	1,83
c. Quick liquidity	times	0,89	1,15
Item	Measurement	Year 2025	Year 2024
<b>6.3. Profitability ratio</b>			
<i>a. Profit margin / revenue ratio</i>			
- Profit before tax / Revenue	%	10,12	7,60
- Profit after tax / Revenue	%	8,08	6,08
<i>b. Return on Assets (ROA)</i>			
- Profit before tax / Total assets	%	7,31	7,86
- Profit after tax / Total assets	%	5,84	6,28
<i>c. Net profit after tax / Owner's equity</i>	%	11,07	8,94



**Appendix 04a - Trade receivables in detail**

No	Customer code	Customer	Previous year		Current year	
			Value	Provision	Value	Provision
1	PKD-1xx-0375	KARUNA PHARMA CO,LTD	6.520.562.745		4.429.531.934	
2	1002056	Trung tâm Y tế Bình Giang	2.482.472.650		3.050.841.914	
3	1002395	Công ty cổ phần Thanh Dược	935.793.512		2.497.096.011	
4	1000603	Công ty cổ phần thương mại và Dược phẩm Nam Việt	1.381.227.118		2.431.067.808	
5	1002062	Trung tâm Y tế Tứ Kỳ	4.355.255.977		2.393.483.260	
6	1001065	Bệnh viện Đa khoa Hải Dương	5.911.196.600		2.339.428.262	
7	1002061	Trung tâm Y tế Nam Sách	7.382.561.150		1.936.770.640	
8	1041614	Công ty cổ phần đầu tư và thương mại 7679	1.322.903.698		1.842.230.166	
9	1036795	Công ty TNHH dược phẩm Hải Nam	184.149.701		1.833.659.044	
10	1037222	BỆNH VIỆN K	25.943.999		1.725.609.999	
11	Others	Others	87.734.104.444		85.388.470.904	
Total			118.236.171.594		109.868.189.942	

**Appendix 04c - Customers pay in advanced**

No	Customer code	Customer	Previous year		Current Year	
			Value	Provision	Value	Provision
1	3000773	CÔNG TY TNHH SOLPHARMA	886.690.000		2.920.150.100	
2	3000906	CÔNG TY CP IPP VIGOR GROUP			2.625.814.076	
3	1000400	Công ty TNHH Thương mại và Công nghệ Hà Minh	3.682.738.650		2.214.177.730	
4	3000913	Công ty TNHH New Star Pharm			1.353.000.000	
5	PKD-1xx-0375	KARUNA PHARMA CO,LTD			1.306.755.000	
6	PKD-1xx-0424	Doo <<Rivulet International>>	267.648.160		1.303.094.079	
7	3000938	Công ty TNHH NOVARA WORLD (Bayer World)...			960.000.000	
8	3000149	Công ty Cổ phần Dược VP-PHARM	478.725.045		917.003.829	
9	3000254	Công ty TNHH Thương mại và dịch vụ 2B	526.757.246		837.592.263	
10	3000730	CÔNG TY CỔ PHẦN VIỆT NAM PHARUSA			831.921.010	
11	3000453	Công ty TNHH SUHAGO Việt Nam	54.769.932		824.141.840	
12	3000687	CÔNG TY TNHH THIÊN Y PHARMA ( Phúc An pharma)			715.470.000	
13	3000632	Công ty cổ phần dược Pavispharm			630.550.000	
14	3000938	Công ty TNHH NOVARA WORLD (Bayer World)...			610.204.320	
15	3000900	CÔNG TY CỔ PHẦN XUẤT NHẬP KHẨU DƯỢC - TRANG			550.000.000	
16	3000538	Nguyễn Văn Thành (Quảng Bình)	500.000.000		500.000.000	
17	Others	Others	20.614.104.123		9.220.110.006	
<b>Total</b>			<b>27.011.433.156</b>		<b>28.319.984.253</b>	



**Appendix 04b - Trade payables in detail**

No	Customer code	Customer	Previous year		Current year	
			Value	Provision	Value	Provision
1	5006608	Công ty TNHH cơ nhiệt điện lạnh Bách Khoa	0	0	5.398.660.354	5.398.660.354
2	3000846	Công ty cổ phần Dược Phúc Thái	0	0	3.652.635.000	3.652.635.000
3	1000395	Công ty TNHH Thương Mại Và Sản Xuất Đông Âu	2.685.110.449	2.685.110.449	3.246.340.931	3.246.340.931
4	1000646	Công ty cổ phần thương mại và tư vấn Cát Vàng	0	0	3.014.460.000	3.014.460.000
5	1000483	Công ty Trách nhiệm hữu hạn Thương mại Dược phẩm Vạn Xuân	3.011.560.416	3.011.560.416	3.011.560.416	3.011.560.416
6	3000471	Công ty Cổ phần Dược phẩm Trung ương CPC1	2.778.300.000	2.778.300.000	2.901.150.000	2.901.150.000
7	1000477	Công ty cổ phần Thủy Tinh Hưng Phú	1.610.031.600	1.610.031.600	2.417.169.600	2.417.169.600
8	1000389	Công Ty TNHH Sản xuất Bao Bì Và Thương Mại Đức Thành	1.715.471.805	1.715.471.805	1.959.930.482	1.959.930.482
9	1045033	Công ty TNHH Dược phẩm Hoa Minh	0	0	1.918.027.000	1.918.027.000
10	1000597	Công ty cổ phần FRESENIUS KABI VIỆT NAM(FRESENIUS KABI VIET NAM JOINT STOCK COMPANY)	3.357.870.838	3.357.870.838	1.757.368.320	1.757.368.320
11	Others	Other payables	48.754.700.987	48.754.700.987	45.655.725.004	45.655.725.004
<b>Total</b>			<b>63.913.046.095</b>	<b>63.913.046.095</b>	<b>74.933.027.107</b>	<b>74.933.027.107</b>

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**

102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**Appendix 04b - Pay for vendors in advanced**

No	Customer No	Customer	Previous year		Current year	
			Value	Provision	Value	Provision
1	5006134	Tofflon Science and Technology Group Co.,Ltd			5.475.835.500	5.475.835.500
2	5006702	Công ty TNHH TM hóa chất DV kỹ thuật Sao Nam			3.585.920.000	3.585.920.000
3	5006403	IMA Pacific Company Limited			3.232.180.224	3.232.180.224
4	5006689	Công ty cổ phần nội thất và dịch vụ phòng thí nghiệm Đông Dương			1.139.332.856	1.139.332.856
5	5006696	Công ty TNHH Ebraco International			1.019.647.620	1.019.647.620
6	5006685	Công ty TNHH SAS CTAMAD			964.580.400	964.580.400
7	1000734	Công Ty cổ phần Công nghiệp MYTEK			727.630.560	727.630.560
8	5006565	Truking Watertown Technology Co., Ltd			406.922.100	406.922.100
9	5006750	Công ty TNHH Vina - Sanwa			293.888.640	293.888.640
10	5006607	Shinva Medical Instrument Co., Ltd	1.002.032.100	1.002.032.100	243.684.454	243.684.454
11	Others	Others	58.669.540.290	58.669.540.290	1.539.152.326	1.539.152.326
Total			59.671.572.390	59.671.572.390	18.628.774.680	18.628.774.680

00110  
ÔNG T  
PH  
C VẬT  
Y TẾ  
IDUON  
WG - TP



**Appendix 05- Taxes and other payables to the State**

	01/01/2025		Payable during the fiscal year	Paid amount during the fiscal year	31/12/2025	
	Receivables	Payables			Receivables	Payables
- Value added tax			61.514.854.934	61.514.854.934		
- Special consumption tax						
- Import and export tax			24.879.183	24.879.183		
- Corporate income tax		6.302.229.077	14.395.113.580	11.561.590.085		9.135.752.572
- Personal income tax		849.808.878	3.143.471.331	3.016.353.962		976.926.247
- Resource tax						
- Real estate tax, land rent			1.307.178.869	1.307.178.869		
- Other taxes			253.881.092	253.881.092		
- Fees, charges and other payables						
<b>Total</b>		<b>7.152.037.955</b>	<b>80.639.378.989</b>	<b>77.678.738.125</b>		<b>10.112.678.819</b>

(\*) Amount of corporate income tax provisionally paid

- Amount of corporate income tax provisionally paid 11.561.590.085  
- Corporate income tax exemption (support female employees)  
- Adjusted corporate income tax at the branch

**Total 11.561.590.085**

Payable amount of corporate income tax settled in the period

- Payable amount of corporate income tax settled in the period 14.061.666.832  
- Adjusted corporate income tax at the branch

**Total 14.061.666.832**

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC**  
102 Chi Lang Street, Thanh Dong Ward, Hai Phong City, Vietnam

**Appendix 06 - Borrowings and finance lease liabilities**

Item	Opening balance	Increase	Decrease	Closing balance
<b>a) Short-term borrowings and finance lease liabilities</b>				
- Short-term borrowings	65.925.328.072	142.261.382.739	141.380.892.965	66.805.817.846
- Overdue borrowings				
- Short-term finance lease liabilities				
<b>b) Long-term borrowings and finance lease liabilities</b>				
- Borrowings	6.002.713.990	231.235.262.352	189.684.200	237.048.292.142
- Long-term finance lease liabilities				

38000  
CÔNG  
CỘ P  
IỘC V  
Y T  
HAI DU  
ÔNG -



**Appendix 07 - Financial risk**

Liquidity risk is the risk that HDPHARMA will encounter difficulty in meeting financial obligations due to a shortage of funds. HDPHARMA's liquidity risk primarily arises from mismatches in the maturities of financial assets and financial liabilities.

HDPHARMA monitors liquidity risk by maintaining a level of cash and cash equivalents deemed adequate by the Board of Directors to finance HDPHARMA's business operations and to mitigate the effects of fluctuations in cash flows.

The maturity information of HDPHARMA's financial liabilities based on undiscounted contractual payments is as follows:

Item	Under 01 year	From 01 to 05 years	Total
<b>Closing balance</b>			
Borrowings	66.805.817.846	237.048.292.142	303.854.109.988
Trade payables	74.933.027.107		74.933.027.107
Accrued expenses	604.089.126		604.089.126
Other payables	7.550.378.347		7.550.378.347
<b>Opening balance</b>			
Borrowings	65.925.328.072	6.002.713.990	71.928.042.062
Trade payables	63.913.046.095		63.913.046.095
Accrued expenses	428.162.066		428.162.066
Other payables	7.182.181.347		7.182.181.347

HDPHARMA considers the concentration of risk regarding debt repayment to be low. HDPHARMA is capable of meeting its maturing debt obligations through cash flows from operating activities and proceeds from maturing financial assets.

